ESMO 2017: Docetaxel-based triplet therapy in gastric cancer: results from the FLOT4 trial confirm superiority over standard care


  • Univadis
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The superiority of docetaxel-based triplet pre-operative therapy (docetaxel., oxaliplatin, leucovorin, and 5-fluorouracil [FLOT regimen]) over standard care (epirubicin, cisplatin, and 5- fluorouracil or capecitabine [ECF/ECX regimen]) in patients with resectable gastric cancer has...